MedTrace Logo

Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

NCT03657420 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-08-14

No results posted yet for this study

Summary

This research study is studying a combination of drugs as a possible treatment for multiple myeloma.

The drugs that will be administered are:

* ABI-009 (nab-rapamycin)
* Pomalidomide
* Dexamethasone

Conditions

Interventions

DRUG

ABI-009

ABI-009 is an mTOR inhibitor. This pathway is believed to be overactive in multiple myeloma.

DRUG

Pomalidomide

Pomalidomide is an immunomodulatory agent and believed to work by affecting the growth signals that keep cancer cells alive.

DRUG

Dexamethasone

Dexamethasone is a steroid which is believed to kill cancer cells

Sponsors & Collaborators

  • Aadi Bioscience, Inc.

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Andrew J. Yee, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-30
Primary Completion
2021-09-30
Completion
2024-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03657420 on ClinicalTrials.gov